吉非替尼联合全脑放疗治疗非小细胞肺癌脑转移的效果及安全性

目的 分析吉非替尼联合全脑放疗治疗非小细胞肺癌脑转移患者的临床效果以及用药安全性.方法 选取2013年1月至2014年12月来本院治疗的非小细胞肺癌脑转移患者40例为研究对象,随机分为对照组和试验组,各20例.对照组全脑放疗进行干预,而试验组应用吉非替尼结合全脑放疗进行治疗.结果 试验组治疗后出现恶心呕吐、四肢无力、红肿瘙痒、头痛头晕等不良状况均优于对照组,差异有统计学意义(P＜0.05).试验组病灶控制率、1年生存率、生存时间等状况均高于对照组,差异有统计学意义(P＜0.05).结论 吉非替尼联合全脑放疗治疗非小细胞肺癌脑转移疾病有着较好的作用价值,明显减少了不良状况的发生,提高了患者的生存质量.

Gefitinib and whole brain radiotherapy for brain metastasis of non-small cell lung cancer

Objective To analyze and study the clinical efficacy and safety of gefitinib and whole brain radiotherapy for brain metastasis of non-small cell lung cancer.Methods 40 patients with brain metastases from non-small cell lung cancer treated at our hospital from December,2014 to January,2013 were selected as study objects and were randomly divided into a control group and an experimental group,20 for each group.The control group took whole brain radiotherapy;in addition,the experimental group were treated with gefitinib.Results After the treatment,fewer patients got nausea and vomiting,limb weakness,swelling and itching,headache,dizziness,and other adverse conditions in the experimental group than in the control group,with statistical differences (P＜0.05).The disease control rate,1 year survival rate,survival time,and other conditions were better in the experimental group than in the control group,with statistical differences (P＜0.05).Conclusions Gefitinib and whole brain radiotherapy for brain metastasis of non-small cell lung cancer is effective and can obviously decrease the incidence of adverse reactions and improve the patients' survival quality.